A citation-based method for searching scientific literature

E Link, S Parish, J Armitage, L Bowman, S Heath, F Matsuda, I Gut, M Lathrop, R Collins. N Engl J Med 2008
Times Cited: 1298







List of co-cited articles
903 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management.
Erik S Stroes, Paul D Thompson, Alberto Corsini, Georgirene D Vladutiu, Frederick J Raal, Kausik K Ray, Michael Roden, Evan Stein, Lale Tokgözoğlu, Børge G Nordestgaard,[...]. Eur Heart J 2015
681
22

The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update.
L B Ramsey, S G Johnson, K E Caudle, C E Haidar, D Voora, R A Wilke, W D Maxwell, H L McLeod, R M Krauss, D M Roden,[...]. Clin Pharmacol Ther 2014
226
21

SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid.
Marja K Pasanen, Mikko Neuvonen, Pertti J Neuvonen, Mikko Niemi. Pharmacogenet Genomics 2006
345
19

The SLCO1B1*5 genetic variant is associated with statin-induced side effects.
Deepak Voora, Svati H Shah, Ivan Spasojevic, Shazia Ali, Carol R Reed, Benjamin A Salisbury, Geoffrey S Ginsburg. J Am Coll Cardiol 2009
302
17


Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin.
L R Brunham, P J Lansberg, L Zhang, F Miao, C Carter, G K Hovingh, H Visscher, J W Jukema, A F Stalenhoef, C J D Ross,[...]. Pharmacogenomics J 2012
129
14

Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study.
Eric Bruckert, Gilles Hayem, Sylvie Dejager, Caroline Yau, Bernard Bégaud. Cardiovasc Drugs Ther 2005
795
13

Interpretation of the evidence for the efficacy and safety of statin therapy.
Rory Collins, Christina Reith, Jonathan Emberson, Jane Armitage, Colin Baigent, Lisa Blackwell, Roger Blumenthal, John Danesh, George Davey Smith, David DeMets,[...]. Lancet 2016
862
13

SLCO1B1 genetic variant associated with statin-induced myopathy: a proof-of-concept study using the clinical practice research datalink.
D F Carr, H O'Meara, A L Jorgensen, J Campbell, M Hobbs, G McCann, T van Staa, M Pirmohamed. Clin Pharmacol Ther 2013
95
12


An assessment by the Statin Muscle Safety Task Force: 2014 update.
Robert S Rosenson, Steven K Baker, Terry A Jacobson, Stephen L Kopecky, Beth A Parker, The National Lipid Association's Muscle Safety Expert Panel. J Clin Lipidol 2014
248
11

The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy.
R A Wilke, L B Ramsey, S G Johnson, W D Maxwell, H L McLeod, D Voora, R M Krauss, D M Roden, Q Feng, R M Cooper-Dehoff,[...]. Clin Pharmacol Ther 2012
219
11


Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type 2 diabetes: a go-DARTS study.
L A Donnelly, A S F Doney, R Tavendale, C C Lang, E R Pearson, H M Colhoun, M I McCarthy, A T Hattersley, A D Morris, C N A Palmer. Clin Pharmacol Ther 2011
130
11

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.
C Baigent, A Keech, P M Kearney, L Blackwell, G Buck, C Pollicino, A Kirby, T Sourjina, R Peto, R Collins,[...]. Lancet 2005
11

Phenotype standardization for statin-induced myotoxicity.
A Alfirevic, D Neely, J Armitage, H Chinoy, R G Cooper, R Laaksonen, D F Carr, K M Bloch, J Fahy, A Hanson,[...]. Clin Pharmacol Ther 2014
114
10

Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin.
M K Pasanen, H Fredrikson, P J Neuvonen, M Niemi. Clin Pharmacol Ther 2007
296
10


Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.
Paul M Ridker, Eleanor Danielson, Francisco A H Fonseca, Jacques Genest, Antonio M Gotto, John J P Kastelein, Wolfgang Koenig, Peter Libby, Alberto J Lorenzatti, Jean G MacFadyen,[...]. N Engl J Med 2008
10

Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association.
Connie B Newman, David Preiss, Jonathan A Tobert, Terry A Jacobson, Robert L Page, Larry B Goldstein, Clifford Chin, Lisa R Tannock, Michael Miller, Geetha Raghuveer,[...]. Arterioscler Thromb Vasc Biol 2019
179
10

The role of coenzyme Q10 in statin-associated myopathy: a systematic review.
Leo Marcoff, Paul D Thompson. J Am Coll Cardiol 2007
322
9

Effect of statins on skeletal muscle function.
Beth A Parker, Jeffrey A Capizzi, Adam S Grimaldi, Priscilla M Clarkson, Stephanie M Cole, Justin Keadle, Stuart Chipkin, Linda S Pescatello, Kathleen Simpson, C Michael White,[...]. Circulation 2013
283
9

Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics.
Yohei Nishizato, Ichiro Ieiri, Hiroshi Suzuki, Miyuki Kimura, Kiyoshi Kawabata, Takeshi Hirota, Hiroshi Takane, Shin Irie, Hiroyuki Kusuhara, Yoko Urasaki,[...]. Clin Pharmacol Ther 2003
384
9

Global analysis of genetic variation in SLCO1B1.
Marja K Pasanen, Pertti J Neuvonen, Mikko Niemi. Pharmacogenomics 2008
134
9

Genomewide Association Study of Statin-Induced Myopathy in Patients Recruited Using the UK Clinical Practice Research Datalink.
Daniel F Carr, Ben Francis, Andrea L Jorgensen, Eunice Zhang, Hector Chinoy, Susan R Heckbert, Joshua C Bis, Jennifer A Brody, James S Floyd, Bruce M Psaty,[...]. Clin Pharmacol Ther 2019
17
52

Impact of OATP transporters on pharmacokinetics.
A Kalliokoski, M Niemi. Br J Pharmacol 2009
585
8

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.
Marc S Sabatine, Robert P Giugliano, Anthony C Keech, Narimon Honarpour, Stephen D Wiviott, Sabina A Murphy, Julia F Kuder, Huei Wang, Thomas Liu, Scott M Wasserman,[...]. N Engl J Med 2017
8

Discontinuation of statins in routine care settings: a cohort study.
Huabing Zhang, Jorge Plutzky, Stephen Skentzos, Fritha Morrison, Perry Mar, Maria Shubina, Alexander Turchin. Ann Intern Med 2013
366
8

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.
Christopher P Cannon, Michael A Blazing, Robert P Giugliano, Amy McCagg, Jennifer A White, Pierre Theroux, Harald Darius, Basil S Lewis, Ton Oude Ophuis, J Wouter Jukema,[...]. N Engl J Med 2015
8

A statin-dependent QTL for GATM expression is associated with statin-induced myopathy.
Lara M Mangravite, Barbara E Engelhardt, Marisa W Medina, Joshua D Smith, Christopher D Brown, Daniel I Chasman, Brigham H Mecham, Bryan Howie, Heejung Shim, Devesh Naidoo,[...]. Nature 2013
145
8

Lack of association between SLCO1B1 polymorphisms and clinical myalgia following rosuvastatin therapy.
Jacqueline S Danik, Daniel I Chasman, Jean G MacFadyen, Fredrik Nyberg, Bryan J Barratt, Paul M Ridker. Am Heart J 2013
57
14

Association between SLCO1B1 T521C polymorphism and risk of statin-induced myopathy: a meta-analysis.
Qian Xiang, Shu-Qing Chen, Ling-Yue Ma, Kun Hu, Zhuo Zhang, Guang-Yan Mu, Qiu-Fen Xie, Xiao-Dan Zhang, Yi-Min Cui. Pharmacogenomics J 2018
19
42

Association Between SLCO1B1 Gene T521C Polymorphism and Statin-Related Myopathy Risk: A Meta-Analysis of Case-Control Studies.
Qingtao Hou, Sheyu Li, Ling Li, Yun Li, Xin Sun, Haoming Tian. Medicine (Baltimore) 2015
44
18

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.
Gregory G Schwartz, P Gabriel Steg, Michael Szarek, Deepak L Bhatt, Vera A Bittner, Rafael Diaz, Jay M Edelberg, Shaun G Goodman, Corinne Hanotin, Robert A Harrington,[...]. N Engl J Med 2018
8

Role of genetics in the prediction of statin-associated muscle symptoms and optimization of statin use and adherence.
Liam R Brunham, Steven Baker, Andrew Mammen, G B John Mancini, Robert S Rosenson. Cardiovasc Res 2018
22
36

Statin Toxicity.
Natalie C Ward, Gerald F Watts, Robert H Eckel. Circ Res 2019
153
8


Independent risk factors for simvastatin-related myopathy and relevance to different types of muscle symptom.
Jemma C Hopewell, Alison Offer, Richard Haynes, Louise Bowman, Jing Li, Fang Chen, Richard Bulbulia, Mark Lathrop, Colin Baigent, Martin J Landray,[...]. Eur Heart J 2020
14
57

A systematic review of statin-induced muscle problems in clinical trials.
Harsha V Ganga, Hanna B Slim, Paul D Thompson. Am Heart J 2014
150
7

Statin-Associated Side Effects.
Paul D Thompson, Gregory Panza, Amanda Zaleski, Beth Taylor. J Am Coll Cardiol 2016
258
7

Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance.
Pertti J Neuvonen, Mikko Niemi, Janne T Backman. Clin Pharmacol Ther 2006
546
7

Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants.
Richard H Ho, Leena Choi, Wooin Lee, Gail Mayo, Ute I Schwarz, Rommel G Tirona, David G Bailey, C Michael Stein, Richard B Kim. Pharmacogenet Genomics 2007
140
7

The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15.
Jian Wei Deng, Im-Sook Song, Ho Jung Shin, Chang-Woo Yeo, Doo-Yeoun Cho, Ji-Hong Shon, Jae-Gook Shin. Pharmacogenet Genomics 2008
82
8


Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): allele frequencies in the Japanese population and functional analysis.
Takashi Nozawa, Miki Nakajima, Ikumi Tamai, Kumiko Noda, Jun-Ichi Nezu, Yoshimichi Sai, Akira Tsuji, Tsuyoshi Yokoi. J Pharmacol Exp Ther 2002
249
7

Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care.
Marianne K DeGorter, Rommel G Tirona, Ute I Schwarz, Yun-Hee Choi, George K Dresser, Neville Suskin, Kathryn Myers, GuangYong Zou, Otito Iwuchukwu, Wei-Qi Wei,[...]. Circ Cardiovasc Genet 2013
120
7

Impact of ABCG2 and SLCO1B1 polymorphisms on pharmacokinetics of rosuvastatin, atorvastatin and simvastatin acid in Caucasian and Asian subjects: a class effect?
Bruce K Birmingham, Sarah R Bujac, Robert Elsby, Connie T Azumaya, Cheryl Wei, Yusong Chen, Rogelio Mosqueda-Garcia, Helen J Ambrose. Eur J Clin Pharmacol 2015
83
8

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update.
J A Johnson, K E Caudle, L Gong, M Whirl-Carrillo, C M Stein, S A Scott, M T Lee, B F Gage, S E Kimmel, M A Perera,[...]. Clin Pharmacol Ther 2017
255
7

Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update.
S A Scott, K Sangkuhl, C M Stein, J-S Hulot, J L Mega, D M Roden, T E Klein, M S Sabatine, J A Johnson, A R Shuldiner. Clin Pharmacol Ther 2013
555
7

Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment.
Edmund Lee, Stephen Ryan, Bruce Birmingham, Julie Zalikowski, Ruth March, Helen Ambrose, Rachael Moore, Caroline Lee, Yusong Chen, Dennis Schneck. Clin Pharmacol Ther 2005
351
7


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.